Lilly’s new obesity pill passes heart safety test in diabetes

The findings, which come amid FDA scrutiny of Foundayo’s safety, will enable Lilly to seek a new clearance in diabetes.

By Jonathan Gardner • April 16, 2026

FDA asks Lilly to evaluate obesity pill’s liver risk

The request, which is part of a just-released approval letter for Foundayo, comes amid an intensifying marketing battle between Lilly and Novo.

By Jonathan Gardner • April 15, 2026

Explore the Trendline➔

Oncology's research boom

More than one quarter of the medcines cleared by the FDA's main review office since 2015 have been cancer drugs, a tally that reflects the advent of cancer immunotherapy as well as continued progress in matching treatment to genetics.

By BioPharma Dive staff

Spyre drug for inflammatory bowel disease shows promise in early study

The therapy, which works similarly to Takeda’s blockbuster Entyvio, showed remission rates that suggest a “best-in-class” profile, the company said. 

By Delilah Alvarado • April 13, 2026

Revolution pancreatic cancer drug nearly doubles survival in key trial

The subject of buyout rumors this year, Revolution posted Phase 3 results one analyst called a “game changer” in a tough-to-treat tumor. 

By Jonathan Gardner • April 13, 2026

Connected medical devices: Smarter care starts here

Connected medical devices are transforming healthcare and clinical trials, driving advances in patient care and next-gen therapies shaping the future.

April 13, 2026

Rethinking dermatology trial design for late-stage success

A smarter approach to dermatology trials—built for durability and real-world impact.

April 13, 2026

Women have awaited a revolution in menopause. It hasn’t arrived.

Persistent barriers are still hindering drug development for a host of menopause symptoms.

By Kelly Bilodeau • April 10, 2026

Terns rebuffed a higher bid before selling to Merck

Regulatory filings show that Terns ultimately accepted an offer 15% lower than a previous proposal as four companies vied for rights to the coveted leukemia drug developer. 

By Jonathan Gardner • April 7, 2026

Under-the-skin Tepezza comparable to infused version in key study, Amgen says

The findings could help Amgen defend Tepezza’s market-leading position against emerging rivals, though some analysts expressed doubt about its competitive standing. 

By Delilah Alvarado • April 6, 2026

Perks persuade participants

The right incentive program can boost clinical trial enrollment and engagement.

April 6, 2026

Pfizer, BioNTech to pause COVID vaccine study due to low enrollment

The trial is tied to a post-marketing commitment that FDA Commissioner Martin Makary put in place last year for all approved COVID vaccines.

By Delilah Alvarado • April 1, 2026

Viridian tumbles on positive data for key eye drug prospect

The data did not meet investor expectations, and could bring “fierce investor debate on commercial feasibility,” according to an analyst.

By Delilah Alvarado • March 31, 2026

Sanofi eczema drug weighed down by mixed results, safety concerns

Despite hitting key goals across three late-stage studies, the drug, which targets the “OX40” ligand, raises safety and efficacy questions that had at least one analyst lower his sales forecast.

By Delilah Alvarado • March 30, 2026

Trustworthy AI in clinical oversight

AI can accelerate clinical work and preserve traceability, but only if users can trust it.

March 30, 2026

AstraZeneca lung drug gets ‘surprise’ win in COPD trials

The treatment, tozorakimab, succeeded where other similar therapies failed and could help a broader group of COPD patients than Dupixent. 

By Jonathan Gardner • March 27, 2026

Maze tumbles despite positive data for kidney disease drug

Investors had reservations about data for a drug that could compete with a candidate from Vertex in APOL1-mediated kidney disease.

By Delilah Alvarado • March 25, 2026

Beam posts positive data on base editing treatment for AATD

Updated data showed the biotech's approach to the rare lung and liver condition helped restore functional protective proteins in a small study.

By Gwendolyn Wu • March 25, 2026

Sarepta sees early success with RNAi drugs from Arrowhead

Long-awaited results from Phase 1/2 studies lifted Sarepta’s stock and, according to the company, suggest potential for two medicines to treat muscle-weakening conditions.

By Kristin Jensen • March 25, 2026

Karyopharm myeloma drug yields mixed data in myelofibrosis trial

Xpovio combined with Incyte’s Jakafi helped on one key measure but missed on other goal in a disorder that, by one analyst’s estimates, could triple the company’s revenue.

By Jonathan Gardner • March 24, 2026

Apogee strengthens case for longer-lasting eczema drug

Company shares climbed by more than 20% on Phase 2 study results suggesting the therapy could provide sustained relief when administered once every three or six months.

By Jonathan Gardner • March 23, 2026

Pfizer, Valneva to seek approval of Lyme disease vaccine despite mixed study results

The partners said the shot produced “clinically meaningful” efficacy despite missing its main study objective, a finding they blamed on a lower-than-expected rate of infections during the trial. 

By Delilah Alvarado • March 23, 2026

Roche stops work on experimental SMA drug

In a letter to European patients, Roche said its decision to end development of “emugrobart” was based on the drug “not consistently” improving muscle growth and motor function in a key study.

By Jacob Bell • March 20, 2026

Lilly’s three-pronged obesity drug hits goal in large diabetes trial

Retatrutide, a possible advance on GLP-1 drugs like Zepbound, significantly cut blood sugar and body weight in the study, a sign it might be similarly impactful against obesity.

By Jonathan Gardner • March 19, 2026

Bicycle to lay off 30% of staff, pivot away from Padcev challenger

The company now expects a longer path to approval than anticipated, leading it to deprioritize a therapy billed as a threat to Pfizer’s fast-selling bladder cancer drug. 

By Jonathan Gardner • March 17, 2026

Pfizer’s Ibrance successor moves forward with new study data

The drug, which one analyst described as a “critical” part of Pfizer’s oncology strategy, represents a possible improvement upon Ibrance and other, similar breast cancer medicines from Eli Lilly and Novartis.

By Kristin Jensen • March 17, 2026